Sorafenib: Targeting Multiple Tyrosine Kinases in Cancer

Overview

Journal Recent Results Cancer Res

Specialty Oncology

Date 2014 Apr 24

PMID 24756790

Citations 25

Authors

Jens Hasskarl

Affiliations

Soon will be listed here.

Abstract

Sorafenib (BAY 43-9006, Nexavar®) is an oral multiple tyrosine kinase inhibitor. Main targets are receptor tyrosine kinase pathways frequently deregulated in cancer such as the Raf-Ras pathway, vascular endothelial growth factor (VEGF) pathway, and FMS-like tyrosine kinase 3 (FLT3). Sorafenib was approved by the FDA in fast track for advanced renal cell cancer and hepatocellular cancer and shows good clinical activity in thyroid cancer. Multiple clinical trials are undertaken to further investigate the role of sorafenib alone or in combination for the treatment of various tumor entities.

Citing Articles

Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth.

Johnson S, Liu D, Ewald J, Robles-Planells C, Pulliam C, Christensen K Cancer Biol Ther. 2024; 25(1):2382524.

PMID: 39054566 PMC: 11275529. DOI: 10.1080/15384047.2024.2382524.

Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.

Cruz S, Iranpur K, Judge S, Ames E, Sturgill I, Farley L Int J Mol Sci. 2024; 25(6).

PMID: 38542325 PMC: 10969893. DOI: 10.3390/ijms25063351.

Development of a sorafenib-loaded solid self-nanoemulsifying drug delivery system: Formulation optimization and characterization of enhanced properties.

Lim C, Lee D, Kim M, Lee S, Shin Y, Ramsey J J Drug Deliv Sci Technol. 2023; 82.

PMID: 37124157 PMC: 10139733. DOI: 10.1016/j.jddst.2023.104374.

Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)--Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy.

Jin C, Yoon M, Jo M, Kim S, Lee J, Kang S Pharmaceutics. 2023; 15(4).

PMID: 37111691 PMC: 10146360. DOI: 10.3390/pharmaceutics15041206.

FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile.

Garciaz S, Hospital M Onco Targets Ther. 2023; 16:31-45.

PMID: 36698434 PMC: 9869913. DOI: 10.2147/OTT.S236740.